NuVasive Announces Second Quarter 2019 Financial Results

Date : 07/30/2019 @ 8:02PM
Source : PR Newswire (US)
Stock : Nuvasive Inc (NUVA)
Quote : 73.77  0.34 (0.46%) @ 10:01PM
After Hours
Last Trade
Last $ 73.77 ◊ 0.00 (0.00%)

NuVasive Announces Second Quarter 2019 Financial Results

Nuvasive (NASDAQ:NUVA)
Historical Stock Chart

6 Months : From Jun 2019 to Dec 2019

Click Here for more Nuvasive Charts.

SAN DIEGO, July 30, 2019 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced financial results for the quarter ended June 30, 2019.

NuVasive Logo

Second Quarter 2019 Highlights

  • Revenue increased 3.7% to $292.1 million, or 4.7% on a constant currency basis;
  • GAAP operating profit margin of 10.3%; Non-GAAP operating profit margin of 16.3%; and
  • GAAP diluted earnings per share of $0.29; Non-GAAP diluted earnings per share of $0.63.

"NuVasive continued to deliver consistent revenue growth in the second quarter 2019, with a notably solid performance from the U.S. Hardware business," said J. Christopher Barry, chief executive officer of NuVasive. "We saw meaningful case volume growth driven by increased surgeon adoption of lateral single-position surgery and NuVasive's innovative X360 system. Our strong profitability results over the first half of the year demonstrate the clear initiatives and focused execution throughout the business and are reflected in our raised full-year 2019 non-GAAP guidance for operating margin and earnings per share."

A full reconciliation of GAAP to non-GAAP financial measures can be found in the tables of this news release.

Second Quarter 2019 Results
NuVasive reported second quarter 2019 total revenue of $292.1 million, a 3.7% increase compared to $281.6 million for the second quarter 2018. On a constant currency basis, second quarter 2019 total revenue increased 4.7% compared to the same period last year.

For the second quarter 2019, both GAAP and non-GAAP gross profit was $214.5 million and GAAP and non-GAAP gross margin was 73.4%. These results compared to the second quarter 2018 GAAP and non-GAAP gross profit of $204.5 million and $204.9 million, respectively, and GAAP and non-GAAP gross margin of 72.6% and 72.8%, respectively.

On a GAAP basis, the Company reported net income of $15.0 million, or diluted earnings per share of $0.29, for the second quarter 2019 compared to a net income of $11.5 million, or diluted earnings per share of $0.22, for the second quarter 2018. On a non-GAAP basis, the Company reported net income of $32.8 million, or diluted earnings per share of $0.63 per share, for the second quarter 2019 compared to net income of $30.3 million, or diluted earnings per share of $0.58 per share, for the second quarter 2018.

Annual Financial Guidance for 2019
The Company updated its full-year 2019 financial guidance to reflect first-half 2019 results.


2019 Guidance Range 1


Prior


Current


 GAAP 

 Non-GAAP 


 GAAP 

 Non-GAAP 

Revenue

 $1.14B - $1.16B 


 $1.14B - $1.16B 


 $1.14B - $1.16B 


 $1.14B - $1.16B 

% Growth - Reported

3.5% - 5.5%


3.5% - 5.5%


3.4% - 5.4%


3.4% - 5.4%

% Growth - Constant Currency2



3.8% - 5.8%




3.8% - 5.8%

Operating margin

9.0% - 9.5%


15.0% - 15.5%


9.1% - 9.5%


15.3% - 15.7%

Earnings per share

 $0.95 - $1.05 


 $2.20 - $2.30 


 $0.93 - $1.03 


 $2.25 - $2.35 

EBITDA margin

20.9% - 21.3%


25.2% - 25.7%


21.2% - 21.5%


25.5% - 25.9%

Tax Rate

~22%


~23%


~24%


~23%



1

Prior guidance reflects the range provided May 1, 2019. Current guidance reflects the range provided July 30, 2019.

2

Constant currency is a measure that adjusts US GAAP revenue for the impact of currency over the same period in the prior year.

 

  • The Company maintains full-year 2019 revenue guidance to be in the range of $1.14 billion to $1.16 billion, which now includes approximately $5 million in year-over-year currency headwinds compared to prior guidance of $4 million. This reflects reported growth in the range of 3.4% to 5.4%, compared with prior guidance of 3.5% to 5.5%. Revenue growth on a constant currency basis remains unchanged at 3.8% to 5.8%;
  • Non-GAAP diluted earnings per share in a range of $2.25 to $2.35, compared with prior guidance of $2.20 to $2.30;
  • Non-GAAP operating profit margin of 15.3% to 15.7%, compared with prior guidance of 15.0% to 15.5%;
  • EBITDA margin of 25.5% to 25.9%, compared with prior guidance of 25.2% to 25.7%; and
  • Non-GAAP effective tax expense rate of approximately 23%.

Supplementary Financial Information
For additional financial detail, please visit the Investor Relations section of the Company's website at www.nuvasive.com to access Supplementary Financial Information.

Reconciliation of Full Year EPS Guidance




2019 Guidance Range  1, 2


2018 Actuals 1


Prior 3


Current 4

GAAP net income per share

$0.24


 $0.95 - 1.05 


 $0.93 - 1.03 

Impact of change to diluted share count



GAAP net income per share, adjusted to diluted Non-GAAP share count

$0.24


 $0.95 - 1.05 


 $0.93 - 1.03 







Business transition costs 5

0.22


0.10


0.11

Non-cash purchase accounting adjustments on acquisitions 6

0.02



Non-cash interest expense on convertible notes

0.32


0.30


0.34

Litigation related expenses and settlements 7

0.65


0.20


0.18

Non-recurring consulting fees 8

0.12



Net loss on strategic investments

0.07



Amortization of intangible assets

0.97


0.95


0.96

Purchase of in-process research and development 9

0.17



European medical device regulation10

0.01


0.10


0.11

Tax effect of adjustments11

(0.56)


(0.40)


(0.38)

Non-GAAP earnings per share

$2.23


 $2.20 - 2.30 


 $2.25 - 2.35 







GAAP Weighted shares outstanding - basic

51,382


51,999


51,954

GAAP Weighted shares outstanding - diluted

52,355


52,991


52,898

Non-GAAP Weighted shares outstanding - diluted 12

52,178


52,718


52,586




1

Items may not foot due to rounding.

2

Prior guidance reflects the range provided May 1, 2019. Current guidance reflects the range provided July 30, 2019.

3

Effective tax expense rate of ~22% applied to GAAP earnings and ~23% applied to Non-GAAP earnings.

4

Effective tax expense rate of ~24% applied to GAAP earnings and ~23% applied to Non-GAAP earnings.

5

Costs related to acquisition, integration and business transition activities which include severance, relocation, consulting, leasehold exit costs, third party merger and acquisitions costs, contingent consideration fair value adjustments, and other costs directly associated with such activities.

6

Represents costs associated with non-cash purchase accounting adjustments, such as acquired inventory fair market value adjustments, which are amortized over the period in which underlying products are sold.

7

Represents the loss recorded in connection with the settlement of the Madsen Medical, Inc. litigation matter, as well as expenses associated with ongoing litigation with a former Board member and his current employer related to various matters, including infringement of the Company's intellectual property.

8

Non-recurring consulting fees associated with the implementation of our state tax-planning strategy.

9

Purchase of an in-process research and development asset which had no future alternative use.

10

Costs related to updating our quality system, product labeling, asset write-offs and product remanufacturing to comply with European medical device regulation.

11

The impact on results from taxes include tax effecting the adjustments above at the statutory rate as well as taking into account discrete items and including those discrete items in the annual effective tax rate calculation. The Company also includes those adjustments that would have benefited the tax rate in lieu of the above adjustments as part of the Company's tax filings. The impact of the changes to the tax rate results in an annual rate of ~43% benefit on a GAAP basis and ~18% on a non-GAAP basis in 2018.

12

Adjusted non-GAAP diluted WASO excludes the impact of dilutive convertible notes and warrants for which the Company is economically hedged through its anti-dilutive bond hedge arrangements.

 

Reconciliation of Non-GAAP Operating Margin %










2019 Guidance Range 1, 2

(in thousands, except %)

2018 Actuals 1


Prior


Current

Non-GAAP Gross Margin % [A]

71.9%


72.5% - 73.0%


72.5% - 73.0%

Non-cash purchase accounting adjustments on acquisitions 3

(0.1%)


0.0%


0.0%

GAAP Gross Margin [B]

71.8%


72.5% - 73.0%


72.5% - 73.0%







Non-GAAP Sales, Marketing & Administrative Expense [C]

51.1%


51.0% - 52.0%


50.8% - 51.7%

Non-recurring consulting fees4

0.6%


0.0%


0.0%

Litigation related expenses5

0.6%


0.7%


0.8%

GAAP Sales, Marketing & Administrative Expense [D]

52.3%


51.7% - 52.7%


51.6% - 52.5%







GAAP and Non-GAAP Research & Development Expense [E]

5.6%


6.0%


6.0%







Litigation related settlements [F]6

2.5%


0.0%


0.0%

Amortization of intangible assets [G]

4.6%


4.3%


4.4%

Purchase of in-process research and development [H]7

0.8%


0.0%


0.0%

European medical device regulation [I]8

0.0%


0.6%


0.5%

Business transition costs [J] 9

1.0%


0.4%


0.5%







Non-GAAP Operating Margin % [A - C - E]

15.1%


15.0% - 15.5%


15.3% - 15.7%







GAAP Operating Margin % [B - D - E - F - G - H - I - J]

4.9%


9.0% - 9.5%


9.1% - 9.5%



 1

Items may not foot due to rounding.

2

Prior guidance reflects the range provided May 1, 2019. Current guidance reflects the range provided July 30, 2019.

3

Represents costs associated with non-cash purchase accounting adjustments, such as acquired inventory fair market value adjustments, which are amortized over the period in which underlying products are sold.

4

Non-recurring consulting fees associated with the implementation of our state tax-planning strategy.

5

Expenses associated with ongoing litigation with a former Board member and his current employer related to various matters, including infringement of the Company's intellectual property.

6

Represents the loss recorded in connection with the settlement of the Madsen Medical, Inc. litigation matter.

7

Purchase of an in-process research and development asset which had no future alternative use.

8

Costs related to updating our quality system, product labeling, asset write-offs and product remanufacturing to comply with European medical device regulation.

9

Costs related to acquisition, integration and business transition activities which include severance, relocation, consulting, leasehold exit costs, third party merger and acquisitions costs, contingent consideration fair value adjustments, and other costs directly associated with such activities.

 

Reconciliation of EBITDA Margin %










2019 Guidance Range1, 5

(in thousands, except %)

2018 Actuals 1, 2


Prior 3


Current4

Net Income

1.1%


4.3% - 4.8%


4.3% - 4.7%

Interest income / expense, net 

3.4%


3.3%


3.3%

Income tax benefit / (expense)

(0.3%)


1.3%


1.5%

Depreciation and amortization

11.8%


12.0%


11.9%

EBITDA Margin

16.0%


20.9% - 21.3%


21.2% - 21.5%

Non-cash stock based compensation

2.3%


2.6%


2.5%

Business transition costs6

1.0%


0.4%


0.5%

Non-cash purchase accounting adjustments on acquisitions7

0.1%


0.0%


0.0%

Litigation related expenses and settlements 8

3.1%


0.7%


0.8%

Non-recurring consulting fees 9

0.6%


0.0%


0.0%

In-process research and development10

0.8%


0.0%


0.0%

European medical device regulation11

0.0%


0.6%


0.5%

Net loss on strategic investments

0.3%


0.0%


0.0%

Adjusted EBITDA Margin

24.3%


25.2% - 25.7%


25.5% - 25.9%



1

Items may not foot due to rounding.

2

Effective tax expense rate of ~43% benefit applied to GAAP earnings and ~18% applied to Non-GAAP earnings.

3

Effective tax expense rate of ~22% applied to GAAP earnings and ~23% applied to Non-GAAP earnings.

4

Effective tax expense rate of ~24% applied to GAAP earnings and ~23% applied to Non-GAAP earnings.

5

Prior guidance reflects the range provided May 1, 2019. Current guidance reflects the range provided July 30, 2019.

6

Costs related to acquisition, integration and business transition activities which include severance, relocation, consulting, leasehold exit costs, third party merger and acquisitions costs, contingent consideration fair value adjustments, and other costs directly associated with such activities.

 7

Represents costs associated with non-cash purchase accounting adjustments, such as acquired inventory fair market value adjustments, which are amortized over the period in which underlying products are sold.

8

Represents the loss recorded in connection with the settlement of the Madsen Medical, Inc. litigation matter, as well as expenses associated with ongoing litigation with a former Board member and his current employer related to various matters, including infringement of the Company's intellectual property.

9

Non-recurring consulting fees associated with the implementation of our state tax-planning strategy.

10

Purchase of an in-process research and development asset which had no future alternative use.

11

Charges represent the costs specific to updating our quality system, product labeling, asset write-offs and product remanufacturing to comply with European medical device regulation.

Reconciliation of GAAP to Non-GAAP Financial Information
Management uses certain non-GAAP financial measures such as non-GAAP earnings per share, non-GAAP net income, non-GAAP operating expenses and non-GAAP operating profit margin, which exclude amortization of intangible assets, business transition costs, purchased in-process research and development, one-time restructuring and related items in connection with acquisitions, investments and divestitures, non-recurring consulting fees, certain litigation expenses and settlements, certain European medical device regulation costs, gains and losses from strategic investments, and non-cash interest expense (excluding debt issuance cost). Management also uses certain non-GAAP financial measures which are intended to exclude the impact of foreign exchange currency fluctuations. The measure constant currency utilizes an exchange rate that eliminates fluctuations when calculating financial performance numbers. The Company also uses measures such as free cash flow, which represents cash flow from operations less cash used in the acquisition and disposition of capital. Additionally, the Company uses an adjusted EBITDA measure which represents earnings before interest, taxes, depreciation and amortization and excludes the impact of stock-based compensation, business transition costs, purchased in-process research and development, one-time restructuring and related items in connection with acquisitions, investments and divestitures, non-recurring consulting fees, certain litigation expenses and settlements, certain European medical device regulation costs, gains and losses on strategic investments, and other significant one-time items.

Management calculates the non-GAAP financial measures provided in this earnings release excluding these costs and uses these non-GAAP financial measures to enable it to further and more consistently analyze the period-to-period financial performance of its core business operations. Management believes that providing investors with these non-GAAP financial measures gives them additional information to enable them to assess, in the same way management assesses, the Company's current and future continuing operations. These non-GAAP financial measures are not in accordance with, or an alternative for, GAAP, and may be different from non-GAAP financial measures used by other companies. Set forth below are reconciliations of the GAAP to non-GAAP financial measures.

For the Three Months Ended June 30, 2019

Reconciliation of GAAP to Non-GAAP Financial Measures

(Unaudited - in thousands, except per share data)









Gross Profit

Operating
Profit

Net Income 

Diluted
EPS

Diluted
WASO 5

Net Income to
Adjusted EBITDA

Reported GAAP

$      214,526

$    30,197

$      14,962

$   0.29

52,460

$                       14,962

% of revenue

73.4%

10.3%





Amortization of intangible assets


12,277

12,277




Litigation related expenses and settlements1


2,031

2,031



2,031

Business transition costs2


1,646

1,646



1,646

European medical device regulation3


1,400

1,400



1,400

Non-cash interest expense on convertible notes



4,374




Tax effect of adjustments 4



(3,881)




Interest expense/(income), net






9,323

Income tax expense






5,921

Depreciation and amortization






33,560

Non-cash stock based compensation






6,901

Adjusted Non-GAAP

$      214,526

$    47,551

$      32,809

$   0.63

52,460

$                       75,744

% of revenue

73.4%

16.3%




25.9%



1

Represents expenses associated with ongoing litigation with a former Board member and his current employer related to various matters, including infringement of the Company's intellectual property.

2

Costs related to acquisition, integration and business transition activities which include severance, relocation, consulting, leasehold exit costs, third party merger and acquisitions costs, contingent consideration fair value adjustments, and other costs directly associated with such activities.

3

Represents costs specific to updating our quality system, product labeling, asset write-offs and product remanufacturing to comply with European medical device regulation.

4

Represents the impact from tax affecting the adjustments above at their statutory tax rate. As of July 30, 2019, the Company estimated an annual tax rate of ~24% on a GAAP basis and ~23% on a non-GAAP basis.

5

Adjusted non-GAAP diluted WASO excludes the impact of dilutive convertible notes and warrants for which the Company is economically hedged through its anti-dilutive bond hedge arrangements.

 

For the Six Months Ended June 30, 2019

Reconciliation of GAAP to Non-GAAP Financial Measures

(Unaudited - in thousands, except per share data)









Gross Profit

Operating
Profit

Net Income

Diluted
EPS

Diluted
WASO 5

Net Income to
Adjusted EBITDA

Reported GAAP

$      414,808

$    50,370

$      24,348

$   0.46

52,471

$                       24,348

% of revenue

73.2%

8.9%





Amortization of intangible assets


25,902

25,902




Litigation related expenses and settlements 1


5,077

5,077



5,077

Business transition costs2


5,479

5,479



5,479

European medical device regulation3


1,732

1,732



1,732

Non-cash interest expense on convertible notes



8,693




Tax effect of adjustments4



(10,814)




Interest expense/(income), net






18,427

Income tax expense






7,238

Depreciation and amortization






67,614

Non-cash stock based compensation






12,618

Adjusted Non-GAAP

$      414,808

$    88,560

$      60,417

$   1.15

52,471

$                     142,533

% of revenue

73.2%

15.6%




25.1%



1

Represents expenses associated with ongoing litigation with a former Board member and his current employer related to various matters, including infringement of the Company's intellectual property.

2

Costs related to acquisition, integration and business transition activities which include severance, relocation, consulting, leasehold exit costs, third party merger and acquisitions costs, contingent consideration fair value adjustments, and other costs directly associated with such activities.

3

Represents costs specific to updating our quality system, product labeling, asset write-offs and product remanufacturing to comply with European medical device regulation.

4

Represents the impact from tax affecting the adjustments above at their statutory tax rate. As of July 30, 2019, the Company estimated an annual tax rate of ~24% on a GAAP basis and ~23% on a non-GAAP basis.

5

Adjusted non-GAAP diluted WASO excludes the impact of dilutive convertible notes and warrants for which the Company is economically hedged through its anti-dilutive bond hedge arrangements.

 

For the Three Months Ended June 30, 2018

Reconciliation of GAAP to Non-GAAP Financial Measures

(Unaudited - in thousands, except per share data)









Gross Profit

Operating
Profit

Net Income

Diluted
EPS

Diluted
WASO 5

Net Income to
Adjusted EBITDA

Reported GAAP

$      204,508

$    28,563

$      11,531

$   0.22

51,956

$                       11,531

% of revenue

72.6%

10.1%





Non-cash purchase accounting adjustments on acquisitions 1

405

405

405



405

Amortization of intangible assets


12,628

12,628




Litigation related expenses and settlements 2


383

383



383

Business transition costs 3


3,998

3,998



3,998

Non-cash interest expense on convertible notes



4,153




Tax effect of adjustments 4



(2,775)




Interest expense/(income), net






9,840

Income tax expense






4,813

Depreciation and amortization






32,061

Non-cash stock based compensation






6,860

Adjusted Non-GAAP

$      204,913

$    45,977

$      30,323

$   0.58

51,956

$                       69,891

% of revenue

72.8%

16.3%




24.8%



1

Represents costs associated with non-cash purchase accounting adjustments, such as acquired inventory fair market value adjustments, which are amortized over the period in which underlying products are sold.

2

Represents the change in the estimated loss contingency recorded in connection with the settlement of the Madsen Medical, Inc. litigation matter, as well as expenses associated with ongoing litigation with a former Board member and his current employer related to various matters, including infringement of the Company's intellectual property.

3

Costs related to acquisition, integration and business transition activities which include severance, relocation, consulting, leasehold exit costs, third party merger and acquisitions costs, contingent consideration fair value adjustments, and other costs directly associated with such activities.

4

Represents the impact from tax affecting the adjustments above at their statutory tax rate. As of July 31, 2018, the Company estimated an annual tax rate of ~33% on a GAAP basis and ~21% on a non-GAAP basis.

5

Adjusted non-GAAP diluted WASO excludes the impact of dilutive convertible notes and warrants for which the Company is economically hedged through its anti-dilutive bond hedge arrangements.

 

For the Six Months Ended June 30, 2018

Reconciliation of GAAP to Non-GAAP Financial Measures

(Unaudited - in thousands, except per share data)









Gross Profit

Operating
Profit

Net (Loss)
Income

Diluted
EPS

Diluted
WASO 6,7

Net Loss to Adjusted
EBITDA

Reported GAAP

$      391,216

$    10,341

$    (15,601)

$ (0.30)

51,292

$                      (15,601)

% of revenue

72.2%

1.9%





Non-cash purchase accounting adjustments on acquisitions 1

810

810

810



810

Non-recurring consulting fees 2


6,084

6,084



6,084

Amortization of intangible assets


25,053

25,053




Litigation related expenses and settlements 3


29,969

29,969



29,969

Business transition costs 4


6,251

6,251



6,251

Non-cash interest expense on convertible notes



8,252




Impairment of strategic investment



9,004



9,004

Tax effect of adjustments 5



(18,884)




Interest expense/(income), net






19,173

Income tax benefit






(5,313)

Depreciation and amortization






64,151

Non-cash stock based compensation






10,994

Adjusted Non-GAAP

$      392,026

$    78,508

$      50,938

$   0.98

51,849

$                     125,522

% of revenue

72.3%

14.5%




23.2%



1

Represents costs associated with non-cash purchase accounting adjustments, such as acquired inventory fair market value adjustments, which are amortized over the period in which underlying products are sold.

2

Non-recurring consulting fees associated with the implementation of our state tax-planning strategy.

3

Represents the loss recorded in connection with the settlement of the Madsen Medical, Inc. litigation matter, as well as expenses associated with ongoing litigation with a former Board member and his current employer related to various matters, including infringement of the Company's intellectual property.

4

Costs related to acquisition, integration and business transition activities which include severance, relocation, consulting, leasehold exit costs, third party merger and acquisitions costs, contingent consideration fair value adjustments, and other costs directly associated with such activities.

5

Represents the impact from tax affecting the adjustments above at their statutory tax rate. As of July 30, 2018, the Company estimated an annual tax rate of ~33% on a GAAP basis and ~21% on a non-GAAP basis.

6

The Company had a GAAP net loss for the six months ended June 30, 2018, and therefore the loss per share was calculated using the basic weighted average shares outstanding. The non-GAAP earnings per share for the six months ending June 31, 2018 was calculated using the diluted weighted average shares outstanding.

7

Adjusted non-GAAP diluted WASO excludes the impact of dilutive convertible notes and warrants for which the Company is economically hedged through its anti-dilutive bond hedge arrangements.

Investor Conference Call
NuVasive will hold a conference call today at 4:30 p.m. ET / 1:30 p.m. PT to discuss the results of its financial performance for the second quarter 2019. The dial-in numbers are 1-877-407-9039 for domestic callers and 1-201-689-8470 for international callers. A live webcast of the conference call will be available online from the Investor Relations page of the Company's website at www.nuvasive.com. After the live webcast, the call will remain available on NuVasive's website through August 30, 2019. In addition, a telephone replay of the call will be available until August 6, 2019. The replay dial-in numbers are 1-844-512-2921 for domestic callers and 1-412-317-6671 for international callers. Please use pin number: 13691950.

NuVasive Investor Day 2019
NuVasive will discuss its corporate strategy, including its innovation roadmap and long-term financial outlook, at its Investor Day on August 8, 2019. A live webcast of NuVasive's Investor Day will be available online from the Investor Relations page of the Company's website at www.nuvasive.com. After the live webcast, a replay of the event and the presentation materials will be available on NuVasive's website.

About NuVasive
NuVasive, Inc. (NASDAQ: NUVA) is the leader in spine technology innovation, focused on transforming spine surgery and beyond with minimally disruptive, procedurally integrated solutions designed to deliver reproducible and clinically-proven surgical outcomes. The Company's portfolio includes access instruments, implantable hardware, biologics, software systems for surgical planning, navigation and imaging solutions, magnetically adjustable implant systems for spine and orthopedics, and intraoperative monitoring service offerings. With more than $1 billion in revenues, NuVasive has approximately 2,600 employees and operates in more than 50 countries serving surgeons, hospitals and patients. For more information, please visit www.nuvasive.com.

Forward-Looking Statements
NuVasive cautions you that statements included in this news release or made on the investor conference call referenced herein that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward looking statements. In addition, this news release contains selected financial results from the second quarter 2019, as well as projections for 2019 financial guidance and longer-term financial performance goals. The Company's results for the second quarter 2019 are prior to the completion of review and audit procedures by the Company's external auditors and are subject to adjustment. In addition, the Company's projections for 2019 financial guidance and longer-term financial performance goals represent initial estimates, and are subject to the risk of being inaccurate because of the preliminary nature of the forecasts, the risk of further adjustment, or unanticipated difficulty in selling products or generating expected profitability. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company's surgical products and procedures by spine surgeons, development and acceptance of new products or product enhancements, clinical and statistical verification of the benefits achieved via the use of NuVasive's products (including the iGA® platform), the Company's ability to effectually manage inventory as it continues to release new products, its ability to recruit and retain management and key personnel, and the other risks and uncertainties more fully described in the Company's news releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.

NuVasive, Inc. 

Consolidated Statements of Operations 

(in thousands, except per share data)










Three Months Ended June 30,


Six Months Ended June 30,

(unaudited)

2019


2018


2019


2018

Revenue








Product revenue

$ 261,381


$ 252,687


$ 505,204


$ 486,202

Service revenue

30,724


28,877


61,677


55,884

Total revenue

292,105


281,564


566,881


542,086

Cost of revenue (excluding below amortization of intangible assets)








Cost of products sold 

57,613


58,202


112,099


113,393

Cost of services

19,966


18,854


39,974


37,477

Total cost of revenue

77,579


77,056


152,073


150,870

Gross profit

214,526


204,508


414,808


391,216

Operating expenses:








Sales, marketing and administrative

152,853


145,658


297,929


292,424

Research and development

17,553


14,856


35,128


29,347

Amortization of intangible assets

12,277


12,628


25,902


25,053

Litigation liability (gain) loss


(1,195)



27,800

Business transition costs

1,646


3,998


5,479


6,251

Total operating expenses

184,329


175,945


364,438


380,875

Interest and other expense, net:








Interest income

327


116


736


250

Interest expense

(9,650)


(9,956)


(19,163)


(19,423)

Other income (expense), net

9


(2,379)


(357)


(12,082)

Total interest and other expense, net

(9,314)


(12,219)


(18,784)


(31,255)

Income (loss) before income taxes

20,883


16,344


31,586


(20,914)

Income tax (expense) benefit

(5,921)


(4,813)


(7,238)


5,313

Consolidated net income (loss)

$   14,962


$   11,531


$   24,348


$ (15,601)









Net income (loss) per share:








Basic

$       0.29


$       0.22


$       0.47


$     (0.30)

Diluted

$       0.29


$       0.22


$       0.46


$     (0.30)

Weighted average shares outstanding:








Basic

51,967


51,356


51,822


51,292

Diluted

52,460


51,956


52,471


51,292

 

NuVasive, Inc. 

Consolidated Balance Sheets 

(in thousands, except par values and share amounts) 






June 30, 2019


December 31, 2018

ASSETS

(Unaudited)



Current assets:




Cash and cash equivalents

$       128,377


$                117,840

Accounts receivable, net of allowances of $16,400 and $16,171, respectively

207,992


196,487

Inventory, net

297,136


273,244

Prepaid income taxes

16,188


16,905

Prepaid expenses and other current assets

14,617


13,733

Total current assets

664,310


618,209

Property and equipment, net

257,438


238,841

Intangible assets, net

227,545


252,048

Goodwill

561,420


561,366

Operating lease right-of-use assets

62,424


Deferred tax assets

4,885


5,263

Restricted cash and investments

2,394


2,395

Other assets

24,894


29,737

Total assets

$    1,805,310


$             1,707,859

LIABILITIES AND EQUITY




Current liabilities:




Accounts payable and accrued liabilities

$       105,710


$                105,877

Contingent consideration liabilities

7,892


7,560

Accrued payroll and related expenses

58,492


59,960

Operating lease liabilities

6,471


Litigation liabilities

3,250


1,415

Income tax liabilities

2,823


4,648

Total current liabilities

184,638


179,460

Senior convertible notes

612,762


602,526

Deferred and income tax liabilities

10,269


4,964

Operating lease liabilities

67,753


Other long-term liabilities

67,164


86,384

Commitments and contingencies




Stockholders' equity:




Preferred stock, $0.001 par value; 5,000,000 shares authorized, none outstanding


Common stock, $0.001 par value; 120,000,000 shares authorized at June 30, 2019 and December 31, 2018, 57,357,083and 56,648,077 issued and outstanding at June 30, 2019 and December 31, 2018, respectively

62


61

Additional paid-in capital

1,413,934


1,397,829

Accumulated other comprehensive loss

(8,552)


(8,628)

Retained earnings

41,589


17,241

Treasury stock at cost; 5,327,656shares and 5,116,496 shares at June 30, 2019 and December 31, 2018, respectively

(584,309)


(571,978)

Total equity

862,724


834,525

Total liabilities and equity

$    1,805,310


$             1,707,859

 

NuVasive, Inc. 

Consolidated Statements of Cash Flows 

(in thousands) 






Six Months Ended June 30,

(unaudited)

2019


2018

Operating activities:




Consolidated net income (loss)

$   24,348


$ (15,601)

Adjustments to reconcile net income (loss) to net cash provided by operating activities:




Depreciation and amortization

67,614


64,151

Impairment of strategic investment


9,004

Amortization of non-cash interest

10,494


9,920

Stock-based compensation

12,618


10,994

Reserves on current assets

8,267


9,444

Other non-cash adjustments

4,329


12,133

Deferred income taxes

5,721


(6,593)

Changes in operating assets and liabilities, net of effects from acquisitions:




Accounts receivable

(11,602)


852

Inventory

(31,856)


(19,615)

Prepaid expenses and other current assets

(2,811)


(2,141)

Accounts payable and accrued liabilities

9,301


8,931

Accrued payroll and related expenses

(3,699)


(6,358)

Litigation liability

1,835


2,150

Income taxes

(1,128)


(53)

Net cash provided by operating activities

93,431


77,218

Investing activities:




Acquisitions and investments

(4,100)


(52,081)

Purchases of intangible assets

(6,827)


(7,682)

Purchases of property and equipment

(65,385)


(53,388)

Net cash used in investing activities

(76,312)


(113,151)

Financing activities:




Proceeds from the issuance of common stock

3,888


5,312

Purchases of treasury stock

(11,702)


(2,222)

Payment of contingent consideration

(809)


(8,900)

Proceeds from revolving line of credit


100,000

Repayments on revolving line of credit


(63,000)

Other financing activities

1,769


(146)

Net cash (used in) provided by financing activities

(6,854)


31,044

Effect of exchange rate changes on cash

271


(837)

Increase (decrease) in cash, cash equivalents and restricted cash

10,536


(5,726)

Cash, cash equivalents and restricted cash at beginning of period

120,235


78,198

Cash, cash equivalents and restricted cash at end of period

$ 130,771


$  72,472

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/nuvasive-announces-second-quarter-2019-financial-results-300893423.html

SOURCE NuVasive, Inc.

Copyright 2019 PR Newswire

Latest NUVA Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.